Dr. Jeffrey Scott Berger, MD

Dr. Berger has a particular interest in the field of platelet and hypercoagulable mechanisms of cardiovascular disease, with research interests that include: (1) the role of platelet activity in patients with different high risk vascular phenotypes, such as cardiac and peripheral atherosclerosis, aneurysmal disease, venous disease, kidney disease, and HIV; (2) regulation of platelet activity during the perioperative period; (3) the clinical and platelet response to antiplatelet and antithrombotic therapeutics; and (4) the study of personalized medicine using the platelet phenotype to guide therapeutics. Dr. Berger has set up a platelet lab to measure platelet activity using various techniques, including whole blood and platelet rich plasma aggregometry, flow cytometry, hematology analysis, and molecular biology using the platelet transcriptome. The overall goal of the lab is to use the platelet phenotype in understanding who is at risk for developing cardiovascular disease and to …determine whether modification of the platelet phenotype can ultimately lower the risk of adverse cardiovascular events.